Redhill Biopharma (RDHL) Stock: Buy, Sell, or Hold?
RDHL - Redhill Biopharma Ltd.
$0.64
-0.01 (-1.29%)
âŧ
5d:
-9.53%
30d:
+9.31%
90d:
-29.98%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Apr 09, 2026
0d
Get Alerted When RDHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RDHL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RDHL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: RDHL is currently trading at $0.64, which is considered fair relative to its 30-day fair value range of $0.57 to $0.73.
Technical Outlook: Technically, RDHL is in a strong downtrend. Immediate support is located at $0.62, while resistance sits at $1.60.
Market Sentiment: RDHL scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19000.00 (+2946093.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RDHL is in a strong downtrend. Immediate support is located at $0.62, while resistance sits at $1.60.
Market Sentiment: RDHL scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19000.00 (+2946093.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.57 -
$0.73
Company Quality Score
37/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: Trading 2946093.2% below Wall St target ($19000.00)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.57 -
$0.73
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$1.60
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1428.57
Wall Street Target
$19000.00
(+2946093.2%)
Revenue Growth (YoY)
58.6%
Profit Margin
-150.0%
Share & Embed Analysis
Last updated: September 13, 2026 9:46 PM ET
Data refreshes hourly during market hours. Next update: 10:46 PM
Data refreshes hourly during market hours. Next update: 10:46 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RDHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilead Raday
SELL
15740000 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
